/

Empresas

In

No verificado

Incyte

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

114 Comunicados de prensa

Ver todos los comunicados de prensa

29/07/2026

Industria

Higiene alimentaria

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis

Fuente

Editor

1.00

0

28/07/2026

Web y redes sociales

Telefonía

Mercado de valores

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Incyte Reports Second Quarter 2026 Financial Results and Provides Business Updates

Fuente

Editor

1.00

0

17/07/2026

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Eventos

Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers

Fuente

Editor

1.00

0

13/07/2026

Eventos

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Fuente

Editor

1.00

0

08/07/2026

Biotecnología

Farmacéutica

Salud

Oncología

Web y redes sociales

Telefonía

Finanzas

Mercado de valores

Incyte to Report Second Quarter Financial Results

Fuente

Editor

1.00

0

06/07/2026

Mercado de valores

Biotecnología

Farmacéutica

Salud

Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio

Fuente

Editor

1.00

0

26/06/2026

Industria

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

Fuente

Editor

1.00

0

13/06/2026

Eventos

Biotecnología

Farmacéutica

Salud

Medicina - Varios

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia

Fuente

Editor

1.00

0

13/06/2026

Eventos

Oncología

Higiene alimentaria

Salud

Medicina - Varios

Farmacéutica

Biotecnología

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

Fuente

Editor

1.00

0

08/06/2026

Web y redes sociales

Mercado de valores

Telefonía

Ciencia

Biotecnología

Farmacéutica

Oncología

Sanidad

Salud

Medicina - Varios

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0